Tetra Radar · FDA Approvals · Decision date
RP1: FDA decision date
Replimune Group Inc (REPL) · 10 April 2026
The Company's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in anti-PD-1 failed melanoma was accepted by the FDA in October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of April 10, 2026.
Source: 8-K of 3 February 2026
The date has passed; Tetra Radar has not recorded an approval.
Replimune Group Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.